Biotech companies with a new proteomics tool for pharma’s drug discovery box have trouble these days to get firms to pay to try it out. But GPC Biotech of Martinsried, Germany, has been successful, recently announcing that it signed up Eli Lilly to test its new yeast three-hybrid technology, LeadCode.

LeadCode, an extension of yeast two-hybrid technology, allows researchers to study small molecule-protein interactions in living cells, enabling them to identify the molecular targets of these compounds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.